Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: To explore the cost-effectiveness of artesunate against quinine based principally on the findings of a large multi-centre trial carried out in Southeast Asia. METHODS: Trial data were used to compare mortality of patients with severe malaria, treated with either artesunate or quinine. This was combined with retrospectively collected cost data to estimate the incremental cost per death averted with the use of artesunate instead of quinine. RESULTS: The incremental cost per death averted using artesunate was approximately 140 USD. Artesunate maintained this high level of cost-effectiveness also when allowing for the uncertainty surrounding the cost and effectiveness assessments. CONCLUSION: This analysis confirms the vast superiority of artesunate for treatment of severe malaria from an economic as well as a clinical perspective.

Original publication

DOI

10.1111/j.1365-3156.2009.02227.x

Type

Journal article

Journal

Trop Med Int Health

Publication Date

03/2009

Volume

14

Pages

332 - 337

Keywords

Antimalarials, Artemisinins, Artesunate, Asia, Southeastern, Cost-Benefit Analysis, Drug Costs, Health Care Costs, Humans, Malaria, Quinine, Treatment Outcome